Key points are not available for this paper at this time.
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy (MP09)1 May 2024MP09-12 A PROSPECTIVE MULTICENTER CLINICAL TRIAL FOR EFFICACY OF MOBILE UROFLOWMETRY IN TREATMENT-NAÏVE BENIGN PROSTATIC HYPERPLASIA UNDERGOING MEDICAL THERAPY: INTERIM RESULTS Sang Hun Song, Jong Ho Park, Hyun Jun Park, Yeonsoo Jeong, Hoyoung Ryu, Jeong Woo Lee, and Sangchul Lee Sang Hun SongSang Hun Song , Jong Ho ParkJong Ho Park , Hyun Jun ParkHyun Jun Park , Yeonsoo JeongYeonsoo Jeong , Hoyoung RyuHoyoung Ryu , Jeong Woo LeeJeong Woo Lee , and Sangchul LeeSangchul Lee View All Author Informationhttps://doi.org/10.1097/01.JU.0001008920.55771.18.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To evaluate the accuracy of an application-based mobile uroflowmetry (UFM) and comparison to inpatient UFM measurements for use during medical therapy for benign prostatic hyperplasia (BPH) METHODS: Total 33 patients with no prior treatment within 4 weeks of visiting the outpatient clinic were prospectively enrolled from 3 tertiary centers. After diagnosis of BPH, participants carried out application UFM measurements using a sound-based mobile application proudP® for at least 4 days during the pre-treatment period. Further measurements were conducted for at least 4 day-periods after 4 and 12 weeks of treatment initiation. In-office measurements were conducted both pre-treatment, post-initiation 1, 4, and 12 weeks, and UFM parameters including maximum flow rate (Qmax) and voided volume (VV) were compared. Satisfaction questionnaires in a 0-10 scale were conducted at 12 week study termination. RESULTS: Interim results of 27 participants with study completion have been analyzed. Baseline Qmax and VV were 15.2±8.1 mL/sec and 238.6±92.4 mL for in-office and 17.0±5.0 mL/sec and 304.7±66.6 mL for application measurements, respectively, with significant correlation (correlation coefficient 0.717, p<0.05). App-based UFM accurately reflected improvement in voiding symptoms over time after initiation of medical treatment with total IPSS decreased by mean 5.7 points and mean Qmax improved by 1.1 mL/sec at 12 weeks. Overall patient satisfaction was high, with mean 9.1±1.2 points at study completion, with older patients over 70 years showing good compliance and satisfaction to application-based measurements. CONCLUSIONS: Application-based UFM measurements well represent treatment response in patients with BPH undergoing medical therapy with good correlation of proudP® measurements to in-patient UFM parameters. This technology may have a crucial role in the era of telemedicine, allowing accurate surveillance of BPH patients with extended follow-periods without necessitating frequent visits to the outpatient clinic. Download PPT Source of Funding: This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: 1711138269, RS-2020-KD000141) (NTIS, RS-2020-KD000141) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e131 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sang Hun Song More articles by this author Jong Ho Park More articles by this author Hyun Jun Park More articles by this author Yeonsoo Jeong More articles by this author Hoyoung Ryu More articles by this author Jeong Woo Lee More articles by this author Sangchul Lee More articles by this author Expand All Advertisement PDF downloadLoading ...
Song et al. (Mon,) studied this question.